Transgene's Novel Vaccine Shows Promise Against Mpox

Transgene has announced promising preclinical results for its new vaccine candidate, TG-MVATM, against monkeypox. The vaccine, derived from a scalable cell-line, demonstrated efficacy, immunogenicity, and safety comparable to existing vaccines in animal models. The findings were presented at the World Congress on Infectious Diseases 2026.

The novel vaccine was evaluated in mice and non-human primate models, showing strong protective effects. Survival rates matched those of currently approved vaccines, with robust immune responses noted in both species. Similar antibody responses were also observed.

Facing growing concerns over poxvirus threats and limited vaccine supplies, Transgene is working to develop TG-MVATM for widespread use. The company plans to advance the vaccine into clinical trials and hopes to provide an additional supply source for mpox and smallpox vaccines.